Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$336M |
| 2 |
Truist Financial
TFC
|
+$144M |
| 3 |
Schwab US Large- Cap ETF
SCHX
|
+$103M |
| 4 |
Schwab US Aggregate Bond ETF
SCHZ
|
+$91.6M |
| 5 |
Home Depot
HD
|
+$90.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$323M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$136M |
| 3 |
VIAB
Viacom Inc. Class B
VIAB
|
+$56.6M |
| 4 |
GWR
Genesee & Wyoming Inc.
GWR
|
+$41.5M |
| 5 |
VSM
Versum Materials, Inc.
VSM
|
+$39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.04% |
| 2 | Financials | 14.33% |
| 3 | Healthcare | 12.99% |
| 4 | Industrials | 10.19% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
StoneX
SNEX
$8.05B
| $4.88M | ﹤0.01% |
505,860
+8,758
| +2% | +$72.5K |
|
|
NPTN
2027
DELISTED
NEOPHOTONICS CORP
NPTN
| $4.87M | ﹤0.01% |
552,581
-6,278
| -1% | -$47K |
|
2028
Adecoagro
AGRO
$1.31B
| $4.86M | ﹤0.01% |
580,668
+43,207
| +8% | +$289K |
|
2029
America's Car Mart
CRMT
$25.7M
| $4.86M | ﹤0.01% |
44,316
-14,145
| -24% | -$1.37M |
|
2030
Virtu Financial
VIRT
$5.05B
| $4.85M | ﹤0.01% |
303,345
+8,206
| +3% | +$135K |
|
2031
Travere Therapeutics
TVTX
$5.79B
| $4.84M | ﹤0.01% |
340,511
+3,076
| +0.9% | +$39.3K |
|
|
GTHX
2032
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $4.83M | ﹤0.01% |
182,880
+3,141
| +2% | +$73.5K |
|
2033
Parsons
PSN
$5.08B
| $4.83M | ﹤0.01% |
117,011
+2,095
| +2% | +$78.2K |
|
2034
1st Source
SRCE
$2.13B
| $4.83M | ﹤0.01% |
92,994
-32,300
| -26% | -$1.62M |
|
2035
Axcelis
ACLS
$4.42B
| $4.82M | ﹤0.01% |
200,045
+2,479
| +1% | +$52.2K |
|
2036
CorVel
CRVL
$3.25B
| $4.82M | ﹤0.01% |
165,414
+1,674
| +1% | +$44.5K |
|
2037
Univest Financial
UVSP
$1.19B
| $4.81M | ﹤0.01% |
179,732
+3,496
| +2% | +$90.5K |
|
2038
Virtus Investment Partners
VRTS
$1.14B
| $4.8M | ﹤0.01% |
39,404
-857
| -2% | -$95.6K |
|
|
XRN
2039
Chiron Real Estate Inc
XRN
$484M
| $4.78M | ﹤0.01% |
72,282
+16,548
| +30% | +$1.04M |
|
2040
Banc of California
BANC
$3.11B
| $4.77M | ﹤0.01% |
277,587
+4,844
| +2% | +$73.2K |
|
|
PEI
2041
DELISTED
Pennsylvania Real Estate Investment Trust
PEI
| $4.77M | ﹤0.01% |
59,621
+1,718
| +3% | +$143K |
|
2042
National Presto Industries
NPK
$987M
| $4.76M | ﹤0.01% |
53,827
+2,235
| +4% | +$194K |
|
|
NE
2043
DELISTED
Noble Corporation
NE
| $4.76M | ﹤0.01% |
3,898,472
+504,944
| +15% | +$604K |
|
|
XENT
2044
DELISTED
Intersect ENT, Inc
XENT
| $4.74M | ﹤0.01% |
190,496
+3,817
| +2% | +$77.4K |
|
2045
Antero Resources
AR
$11.3B
| $4.74M | ﹤0.01% |
1,661,116
+311,894
| +23% | +$796K |
|
2046
Alaunos Therapeutics
TCRT
$4.86M
| $4.72M | ﹤0.01% |
6,670
+157
| +2% | +$108K |
|
2047
Upland Software
UPLD
$17.9M
| $4.72M | ﹤0.01% |
13,220
+231
| +2% | +$86.3K |
|
|
ONIT
2048
Onity Group
ONIT
$330M
| $4.71M | ﹤0.01% |
229,220
+9,078
| +4% | +$220K |
|
2049
Great Southern Bancorp
GSBC
$888M
| $4.68M | ﹤0.01% |
73,984
-4,663
| -6% | -$282K |
|
|
EXTN
2050
DELISTED
Exterran Corporation
EXTN
| $4.67M | ﹤0.01% |
595,833
+131,576
| +28% | +$1.22M |
|
Similar funds
Charles Schwab's Q4 2019 Portfolio in Review
As of Q4 2019, Charles Schwab held 3,227 positions worth $186B, up 9.8% from $169B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 3%. Charles Schwab opened 50 new positions and exited 48, leaving the 3,227-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q4 2019 buy was Apollo Global Management: 821,197 shares worth $39.2M.
- Charles Schwab added most to Bristol-Myers Squibb in Q4 2019, an estimated $336M increase.
- Charles Schwab's biggest Q4 2019 reduction was Bank of America, cutting an estimated $34M.
- Charles Schwab fully exited Celgene Corp in Q4 2019, selling an estimated $323M.
- Charles Schwab's ten largest holdings make up 16% of its $186B portfolio in Q4 2019.
- Charles Schwab opened 50 new positions and closed 48 in Q4 2019.
- Charles Schwab's portfolio value rose 9.8% quarter-over-quarter to $186B.
Based on Charles Schwab's 13F filing for Q4 2019, filed 7 Feb 2020.